Last reviewed · How we verify
TLL-018
TLL-018 is a small molecule that targets the SGLT2 receptor.
TLL-018 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | TLL-018 |
|---|---|
| Also known as | Sequence 1, Sequence 2, Sequence 3, extended-release tablet, TLL-018 tablets |
| Sponsor | Hangzhou Highlightll Pharmaceutical Co., Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
TLL-018 works by inhibiting the SGLT2 receptor, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine, resulting in reduced blood glucose levels. By targeting SGLT2, TLL-018 provides a novel approach to treating diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
- Increased risk of urinary tract infections
- Dehydration
Key clinical trials
- A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis (PHASE3)
- A Study of Efficacy and Safety of TLL-018 in CSU Participants (PHASE3)
- The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis (PHASE2)
- Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. (PHASE1)
- Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects (PHASE1)
- A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (PHASE3)
- Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis (PHASE1)
- The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TLL-018 CI brief — competitive landscape report
- TLL-018 updates RSS · CI watch RSS
- Hangzhou Highlightll Pharmaceutical Co., Ltd portfolio CI